Leukemia

Papers
(The H4-Index of Leukemia is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Quantifying measurable residual disease correctly3426
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis3216
CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL190
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/− lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study147
The 5th edition of the WHO classification of haematolymphoid tumors: comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH)124
Key regulatory roles of PRDM1 in human NK-cell differentiation and activation124
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial111
MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel110
Rheumatoid arthritis and the risk of hematologic malignancies: a nationwide cohort study108
Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study98
AI-based hematological malignancy prediction from peripheral blood smears in a large diagnostic laboratory cohort96
Bidirectional anti-tumor and immunological strategies by targeting GARP–TGF-β axis in adult T-cell leukemia/lymphoma91
Invasive fungal diseases impact on outcome of childhood ALL – an analysis of the international trial AIEOP-BFM ALL 200991
Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma87
Correction: Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR1587
Real life evaluation of AlphaMissense predictions in hematological malignancies87
Diverse mechanisms of leukemogenesis associated with PAX5 germline mutation83
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)82
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial82
Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia81
Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms78
Clonal medicine targeting DNA damage response eradicates leukemia76
An MDM2 degrader for treatment of acute leukemias76
Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma70
Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis69
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia67
Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms67
MCL1 as a therapeutic vulnerability in Burkitt lymphoma66
Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core66
Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide66
Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation64
Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia64
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation62
Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers60
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche60
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial60
Real-time genomic characterization of pediatric acute leukemia using adaptive sampling56
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies56
Essential role of Dhx16-mediated ribosome assembly in maintenance of hematopoietic stem cells55
DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells53
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase52
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries52
Cohesin mutations in acute myeloid leukemia51
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma51
Combining lenalidomide with erythropoiesis stimulating agents: a party of one50
Nucleic acid therapeutics as differentiation agents for myeloid leukemias50
STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells50
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN)49
Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia49
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia49
Response to Pfirrmann et al.’s comment on How should we interpret conclusions of TKI-stopping studies49
Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation49
0.17757487297058